Isolation of three new pyrones from Myrothecium verrucaria showed notable antifungal activity, suggesting potential for drug development.
Myrothecium species have been recognized as prolific producers of biologically active secondary metabolites. Despite this, a substantial portion of their biosynthetic potential remains untapped. In this study, Myrothecium verrucaria ACCC 38039 was cultivated on a rice‐based medium at 25°C for 30 days to explore its secondary metabolite profile. Seven compounds were isolated and purified by high‐performance liquid chromatography, including three previously undescribed α‐pyrone derivatives (compounds 1 – 3 ) and four known trichothecenes (compounds 4 – 7 ). The structures of these compounds were elucidated through one‐ and two‐dimensional nuclear magnetic resonance spectroscopy and high‐resolution electrospray ionization mass spectrometry. Among these newly identified pyrones, compound 1 exhibited notable antifungal activity, with a minimum inhibitory concentration of 16 µg/mL against both Aspergillus niger and Candida albicans , underscoring its potential as a promising lead compound for antifungal drug development.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: